David Pengilly, MD
Family Medicine · Bismarck, NDNPI 1710099114
Payments from drug & device makers
Across 662 payments — averaging $12.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- AstraZeneca$1K
- Amgen$983
- Pfizer$875
- AbbVie$829
- Novo Nordisk$815
- plus $2K from 31 others
What the payments were for
- Food & beverage$8,085100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 117 | $1,129 |
| AstraZeneca | 10 | $1,039 |
| Amgen | 85 | $983 |
| Pfizer | 93 | $875 |
| AbbVie(2 entities) | 69 | $829 |
| Novo Nordisk | 124 | $815 |
| Astellas Pharma US Inc | 24 | $419 |
| Dexcom, Inc. | 15 | $270 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $251 |
| Boehringer Ingelheim | 22 | $236 |
| E.r. Squibb & Sons, L.L.C. | 7 | $124 |
| GSK | 7 | $108 |
| Novartis | 7 | $100 |
| Bayer | 7 | $100 |
| Merck | 6 | $91 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $67 |
| Johnson & Johnson | 5 | $61 |
| Phathom Pharmaceuticals, Inc. | 6 | $60 |
| Lexicon Pharmaceuticals, Inc. | 4 | $56 |
| Daiichi Sankyo Inc. | 3 | $56 |
| Actelion Pharmaceuticals US, Inc. | 3 | $52 |
| Sanofi-aventis U.S. LLC | 4 | $51 |
| Radius Health, Inc. | 3 | $38 |
| Axsome Therapeutics, Inc. | 2 | $36 |
| Eisai Inc. | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Medtronic | 1 | $20 |
| Abbott | 1 | $17 |
| Ardelyx, Inc. | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Roche Diagnostics Corporation | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Phadia US Inc. | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,085 in reported general payments places this provider in the 95th percentile of 337 family medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 146 | $152,758 |
| EliquisApixaban | 168 | $112,088 |
| JardianceEmpagliflozin | 85 | $72,699 |
| TrulicityDulaglutide | 38 | $48,677 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 59 | $37,240 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 116 | $36,204 |
| FarxigaDapagliflozin Propanediol | 39 | $25,322 |
| MounjaroTirzepatide | 19 | $18,873 |
| BriviactBrivaracetam | 12 | $18,329 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $18,136 |
| MyrbetriqMirabegron | 24 | $17,779 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $17,415 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 73 | $16,392 |
| XareltoRivaroxaban | 11 | $10,978 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $10,573 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $815 | $152,758146 claims |
| PfizerEliquis, Premarin | $875 | $115,071179 claims |
| GSKArexvy, Trelegy Ellipta, Shingrix, Breo Ellipta, Twinrix | $108 | $87,434287 claims |
| Boehringer IngelheimJardiance, Synjardy | $236 | $79,04496 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,129 | $67,55157 claims |
| AstraZenecaFarxiga | $1,039 | $25,32239 claims |
| Astellas Pharma US IncMyrbetriq | $419 | $17,77924 claims |
| Johnson & JohnsonXarelto | $61 | $10,97811 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $51 | $9,64111 claims |
| MerckJanuvia | $91 | $7,24012 claims |
| AbbVieLinzess | $829 | $5,99111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 337 family medicine providers in North Dakota.
Other family medicine in Bismarck
- Jacqueline QuisnoBismarck$19K
- Jeffrey SmithBismarck$15K
- Stuart SmithBismarck$8K
- Biron BakerBismarck$8K
- Michelle TincherBismarck$7K
- Kevin LongieBismarck$6K
- Kelly LongieBismarck$5K
- Sherry SteinBismarck$5K
- David FieldBismarck$5K
- Brandon PriceBismarck$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.